Teva Pharmaceuticals’ (NYSE: TEVA) first quarter 2020 results beat consensus estimates. The drugmaker reported adjusted earnings of $0.76 per share on revenue of $4.4 billion. Wall Street expected Teva to earn $0.59 per share on revenue of $4.15 billion. TEVA stock surged about 7% in the pre-market trading session.
GAAP net income attributable to ordinary shareholders was $69 million or $0.06 per share in the first quarter of 2020, compared to GAAP net loss of $105 million or $0.10 per share in the first quarter of 2019.
The Tel Aviv, Israel-based company confirmed its outlook for fiscal 2020. EPS is expected to be between $2.30 and $2.55, while revenue is targeted to be in the range of $16.6 billion to $17 billion for fiscal 2020.
Biocept (NASDAQ: BIOC) reported a narrower loss in the second quarter of 2020. The company's revenue declined by 23% year-over-year to $917,000, hurt by the COVID-19 pandemic. BIOC stock slumped
Lyft Inc (NASDAQ: LYFT) reported second-quarter financial results after the closing bell on Wednesday. The ride-hailing company reported a 61% dip in Q2 revenues to $339.3 million, narrowly beating Wall
https://www.youtube.com/watch?v=AFttiM-lTuY&t=138s Network gear maker Cisco Systems, Inc. (NASDAQ: CSCO) on Wednesday announced financial results for the fourth quarter of fiscal 2020, reporting a decline in earnings and revenues. However, the